RxDoctor Payments Data

Lauren Acevedo Molina, MD

Infectious Disease · San Juan, PRNPI 1316333669

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 24.3% of the total. 2025 is the largest year on record at $600, more than ten times the $38 reported in 2020.

$1,724in general payments, 2019–2025

Across 82 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$419
  • Gilead$382
  • Insmed, Inc.$233
  • Melinta Therapeutics, LLC$161
  • Viiv Healthcare Company$137
  • Merck$135
  • plus $257 from 4 others
$25,500in research payments, 2019–2025

Across 2 payments — averaging $12,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$26K

What the payments were for

  • Food & beverage$1,70899%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,724 in reported general payments places this provider in the 70th percentile of 127 infectious disease providers in Puerto Rico.

See all infectious disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$324,040
Medicare patients
762
Services billed
119,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala58$228,222
JulucaDolutegravir/Rilpivirine11$41,357
Daptomycin20$34,822
Cefepime Hcl21$4,919
MicafunginMicafungin Sodium14$3,287
CeftriaxoneCeftriaxone Sodium35$2,181
Cephalexin18$1,166
Levofloxacin19$1,094
Doxycycline Hyclate36$927
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$698
Doxycycline Monohydrate11$593
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim35$398
Fluconazole13$165
Metronidazole11$150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$382$228,22258 claims
Viiv Healthcare CompanyJuluca$137$41,35711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 127 infectious disease providers in Puerto Rico.

Other infectious disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →